Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use
|
|
- Arline Hall
- 5 years ago
- Views:
Transcription
1 IPAR Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use Ginkgoforce Memory & Circulation Ginkgo Tablets Extract (as dry extract) from fresh leaves of Ginkgo biloba (Ginkgo biloba L.) TR No 0725/016/001 TR holder Bioforce (UK) Ltd I INTRODUCTION Date <Date of last revision, month, year) Specific provisions were introduced for traditional herbal medicinal products (THMPs) in accordance with the Traditional Herbal Medicinal Products Directive (2004/24/EC). The national regulations, the Medicinal Products (Control of Placing on the Market) Regulations 2007 (S.I. No. 540 of 2007) which implement this Directive came into force on 23rd July Consequently the HPRA has established the Traditional Herbal Medicinal Products Registration Scheme. The Public Assessment Report reflects the scientific conclusion reached by the Health Products Regulatory Authority (HPRA) at the end of the evaluation process and provides a summary of the grounds for approval of a Certificate of Traditional Use Registration for a specific traditional herbal medicinal product for human use. It is made available by the HPRA for information to the public, after deletion of commercially sensitive information. The legal basis for its creation and availability is contained in Article 21 of EC Directive 2001/83/EC, as amended by Directive 2004/27/EC and Directive 2004/24/EC. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the traditional herbal medicinal product for marketing in Ireland. Based on the review of the data on quality, safety and traditional use, the HPRA has granted Bioforce (UK) Ltd a Certificate of Traditional Use Registration for Ginkgoforce Memory & Circulation Ginkgo tablets containing 90mg of dry ethanolic extract of fresh Ginkgo biloba L. leaf (3-5:1). This application was submitted as a standard application according to Article 16c of Directive 2001/83/EC, as amended, as part of the Traditional Herbal Medicinal Product Registration Scheme. The Summary of Product Characteristics (SmPC) for this traditional herbal medicinal product is available on the HPRA s website. II QUALITY ASPECTS This application is for Ginkgoforce Memory & Circulation Ginkgo tablets. The active ingredient of Ginkgoforce Memory & Circulation Ginkgo tablets is an extract obtained from the leaves of the tree Ginkgo biloba L. Each tablet contains 90mg of extract (as dry extract) from Ginkgo biloba L. fresh leaf (3-5:1). Extraction solvent: Date Printed 28/10/2015 CRN page number: 1
2 Ethanol 60% m/m. II.1 S.1 Herbal Substance The herbal substance specification is considered adequate to control the quality and meets current pharmacopoeial requirements. Batch analytical data demonstrating compliance with this specification has been provided. II.2 S.2 Herbal preparation The herbal preparation is an extract (as dry extract) from the fresh Ginkgo biloba leaves (Ginkgo biloba L.), and is manufactured in accordance with the principles of good manufacturing practice (GMP). The herbal preparation specification is considered adequate to control the quality and meets current pharmacopoeial requirements. Batch analytical data demonstrating compliance with this specification has been provided. II.3 Medicinal product P.1 Composition The composition of the medicinal product is stated in sections 2 and 6.1 of the SmPC. A description of the product is included in section 3 of the SmPC. P.2 Pharmaceutical Development The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines. P.3 Manufacture of the Product The product is manufactured in accordance with the principles of GMP at suitably qualified manufacturing sites. The manufacturing process has been validated according to relevant European guidelines and the process is considered to be sufficiently validated. P.4 Control of Other Substances (Excipients) All ingredients comply with Ph. Eur. or are adequately controlled by the manufacturer s specifications... P.5 Control of Finished Product The Finished Product Specification is based on the pharmacopoeial monograph for tablets, and the tests and control limits are considered appropriate for this type of product. The analytical methods used are described in sufficient detail and are supported by validation data. Batch analytical data for a number of batches from the proposed production site(s) have been provided, and Date Printed 28/10/2015 CRN page number: 2
3 demonstrate the ability of the manufacturer to produce batches of finished product of consistent quality. P.6 Packaging material The approved packaging for this product is described in section 6.5 of the SmPC. Evidence has been provided that the amber glass bottles comply with Ph. Eur. requirements for use with foodstuffs. P.7 Stability of the Finished Product Stability data on the finished product in the proposed packaging have been provided in accordance with EU guidelines and support the shelf-life and storage conditions listed in sections 6.3 and 6.4 of the SmPC. II.4 Conclusion on quality The important quality characteristics of the product are well-defined and controlled. Satisfactory pharmaceutical documentation has been provided, assuring consistent quality of Ginkgoforce Memory & Circulation Ginkgo tablets. III NON-CLINICAL ASPECTS Ginkgoforce Memory & Circulation Ginkgo tablets is a traditional herbal medicinal product as defined by Article 16a (1) of Directive 2001/83/EC, as amended. An expert report on safety has been provided which includes an appropriate review of the available literature. An in vitro study has shown the aqueous ethanolic Ginkgo extract used in this product to be non-mutagenic in the Salmonella typhimurium reverse mutation assay up to the dose of 5,000 µg/plate. No other new preclinical studies have been submitted. Given the type of application and limited data available, it is not possible to assess if the safety package for the phytochemical constituents of Ginkgoforce Memory & Circulation Ginkgo tablets are acceptable to the standards of today s GLP and safety testing requirements. Overall the information presented demonstrating traditional use is considered to be acceptable and the lack of provision of a complete standard safety package is in line with the EMA Guideline on Non-clinical Documentation for Herbal Medicinal Products in Applications for Marketing Authorisation (bibliographical and mixed applications) and in Applications for Simplified Registration (EMEA/HMPC/32116/05). An environmental risk assessment is not required for herbal medicinal products according to guidance CPMP/SWP/4447/00. IV CLINICAL ASPECTS This is a national application submitted by Bioforce (UK) Ltd under Article 16a of Directive 2001/83/EC, as amended. Ginkgoforce Memory & Circulation Ginkgo tablets is a traditional herbal medicinal product used to alleviate agerelated memory loss and the symptoms of poor blood flow in conditions such as cold hands and feet. This is exclusively based on long-standing use. Prior to use, other serious conditions should have been ruled out by a medical doctor. This product is for use in adults and older people. IV.1 Clinical Efficacy There is no requirement under the Traditional Herbal Registration Scheme to prove scientifically that the product is efficacious, the registration is based exclusively upon the long-standing use of Ginkgoforce Memory & Circulation Ginkgo tablets as a traditional herbal medicine and not upon data generated from clinical trials. Article 16c1(c) of Directive 2001/83/EC requires the applicant to provide bibliographic or expert evidence to show that Date Printed 28/10/2015 CRN page number: 3
4 the medicinal product in question, or a corresponding product, has been in medicinal use throughout a period of at least 30 years, including at least 15 years within the Community. With regard to this traditional use data, the requirements of Article 16c1(c) have been met. The efficacy of this traditional herbal medicinal product is plausible on the basis of long standing use and experience. The indication proposed for Ginkgoforce Memory & Circulation Ginkgo tablets is in line with traditional indications recorded and hence, compatible with the requirements of the Traditional Herbal Medicinal Products Directive 2004/24/EC. IV.2 Clinical Safety In accordance with Article 16c1(d) the applicant has provided a bibliographic review of the safety data together with an expert report. If symptoms persist beyond 2 weeks or worsen, a qualified healthcare professional should be consulted. This product should not be used in those who are allergic to Ginkgo preparations or any of the excipients listed in the SmPC. It should also not be used in women who are pregnant, may become pregnant or those who are breast-feeding. This product should not be used in children and adolescents under 18 years of age because the available data are not sufficient and medical advice should be sought. Concomitant use of Ginkgo biloba preparations with Efavirenz or Nifedipine is not recommended. The following adverse reactions have rarely been reported in association with the use of products containing Ginkgo biloba extract. Immune system disorders Allergy Nervous system disorders Headaches Dizziness Gastrointestinal disorders Nausea Vomiting Diarrhoea Abdominal pain Skin and subcutaneous tissue disorders Pruritis Rash There have been very rare reports of Stevens-Johnson syndrome associated with the use of Ginkgo extract. There are also sporadic case reports of bleeding in patients who have been taking preparations containing Ginkgo extract. Care should be taken by patients who are at an increased risk of bleeding. It is advisable that Ginkgo biloba preparations are discontinued at least 2 weeks prior to surgery. In patients with epilepsy, onset of further seizures - promoted by the intake of Ginkgo preparations - cannot be excluded. In conclusion, this product proves not to be harmful in the specified conditions of use based on the review of safety Date Printed 28/10/2015 CRN page number: 4
5 data, expert report and additional data provided. IV.3 Pharmacovigilance It should be noted that in accordance with Article 16g of Directive 2001/83/EC, as amended, the pharmacovigilance requirements described in Articles of Directive 2001/83/EC, as amended, also apply in respect of traditional herbal medicinal products. V OVERALL CONCLUSIONS The important quality characteristics of the product are well-defined and controlled. Satisfactory pharmaceutical documentation has been provided, assuring consistent quality of Ginkgoforce Memory & Circulation Ginkgo tablets. The HPRA, on the basis of the data submitted, considered that Ginkgoforce Memory & Circulation Ginkgo tablets demonstrated adequate evidence of traditional use for the approved indications and no new preclinical or clinical safety concerns have been identified. A certificate of traditional use registration for Ginkgoforce Memory & Circulation Ginkgo tablets is granted. Date Printed 28/10/2015 CRN page number: 5
Health Products Regulatory Authority IPAR. Public Assessment Report for a. Traditional Herbal Medicinal Product
IPAR Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use Ginkgo-Biloba Pharma Nord film-coated tablets Ginkgo dry extract TR 1242/1/1 TR holder Pharma Nord ApS March 2018
More informationPublic Assessment Report for a Traditional Herbal Medicinal Product for Human Use
IPAR Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use Venaforce Varicose Veins gastro-resistant tablets Dry extract from fresh Aesculus hippocastanum L., semen (Horse Chestnut
More informationPublic Assessment Report for a Traditional Herbal Medicinal Product for Human Use
IPAR Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use Agnus castus oral drops Tincture of Agnus castus fruit TR2309/017/001 A. Vogel Ireland Limited 28 November 2018 CRN008R68
More informationPublic Assessment Report for a Homeopathic Medicinal Product for Human Use
IPAR Public Assessment Report for a Homeopathic Medicinal Product for Human Use Teetha Teething Gel HOA1149/007/001 HOA holder: A. Nelson & Company Limited Date: 16 November 2018 16 November 2018 CRN008K7Z
More informationPublic Assessment Report for a Homeopathic Medicinal Product for Human Use
IPAR Public Assessment Report for a Homeopathic Medicinal Product for Human Use Nelsons Arnicare Arnica Cream HOA1149/008/001 HOA holder: A Nelson & Company Limited Date 09.11.2018 9 November 2018 CRN008K80
More informationPublic Assessment Report for a Homeopathic Medicinal Product for Human Use
IPAR Public Assessment Report for a Homeopathic Medicinal Product for Human Use Nelsons Rhus tox Cream HOA1149/010/001 HOA holder: A Nelson & Company Limited Date 09.11.2018 9 November 2018 CRN008K81 Page
More informationIrish Medicines Board IPAR IRISH MEDICINES BOARD PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE. Scientific discussion.
IPAR IRISH MEDICINES BOARD PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE Scientific discussion Arkovox Syrup IVY LEAF DRY EXTRACT (HEDERA HELIX L.) (4-6:1) EXTRACTION SOLVENT: ETHANOL
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Atrosan Devil's Claw film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 480 mg of extract
More informationHealth Products Regulatory Authority IPAR. Public Assessment Report for a Medicinal Product for Human Use. Scientific discussion
IPAR Public Assessment Report for a Medicinal Product for Human Use Scientific discussion Advil Cold & Flu Coated Tablets Ibuprofen 200mg Pseudoephedrine Hydrochloride 30mg PA0822/164/001 The Public Assessment
More informationPackage Insert. Cognitin
Package Insert Cognitin Product Summary 1. Name of the medicinal product Cognitin 2. Qualitative and quantitative composition Each film coated tablet contains extract 60 mg 5mg 3. Pharmaceutical form Film
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Hypermin, tablet [Hypericum perforatum L., (St. John s wort) herba recens, dry extract (3.1-4.0:1) ethanol 60 %] Asp. no: 2008-1034 This module reflects the
More informationPublic Assessment Report Scientific discussion. Ginsana, oral solution. Asp.no.:
Läkemedelsverket 2014-04-15 Public Assessment Report Scientific discussion Ginsana, oral solution (Panax ginseng C.A. Meyer, radix, standardised dry extract G115 Pharmaton (0.9-3.9:1, 40% ethanol)) Asp.no.:
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Cynaramin, oral drops, solution (Peumus boldus Molina, folium, liquid extract, (1:10); Taraxacum officinale Web., radix and herba, liquid extract, (1:17))
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Prostasan soft capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 320 mg of extract (as soft extract) from Serenoa
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Echinaforce Cold and Flu chewable tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: 5.9 mg of dry extract from
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL
European Medicines Agency Evaluation of Medicines for Human Use London, 6 November 2008 Doc. Ref.: EMEA/HMPC/251323/2006 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationPublic Assessment Report Scientific discussion. Echinaforce Forte, tablet. Asp. No:
Public Assessment Report Scientific discussion Echinaforce Forte, tablet Echinacea purpurea (L.) Moench (purple coneflower) herba recens, dry extract (17-34:1) and Echinacea purpurea (L.) Moench (purple
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON PASSIFLORA INCARNATA L., HERBA
European Medicines Agency Evaluation of Medicines for Human Use London, 7 September 2007 Doc. Ref: EMEA/HMPC/230962/2006 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationDormeasan, oral drops, solution (Valeriana officinalis L., radix, tincture; Humulus lupulus L., strobulus, tincture)
Public Assessment Report Scientific discussion Dormeasan, oral drops, solution (Valeriana officinalis L., radix, tincture; Humulus lupulus L., strobulus, tincture) Asp. No: 2008-1029 This module reflects
More informationHealth Products Regulatory Authority IPAR. Public Assessment Report. Scientific discussion
IPAR Public Assessment Report Scientific discussion Magnaspartate 243mg Powder for Oral Solution MAGNESIUM ASPARTATE DIHYDRATE IE/H/436/001/DC Date: 3 rd November 2014 This module reflects the scientific
More informationPublic Assessment Report Scientific discussion. Ginsana, soft capsule. Asp.no.:
Läkemedelsverket 2014-04-15 Public Assessment Report Scientific discussion Ginsana, soft capsule (Panax ginseng C.A. Meyer, radix, standardised dry extract G115 Pharmaton (0.9-3.9:1, 40% ethanol)) Asp.no.:
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON BETULA PENDULA ROTH; BETULA PUBESCENS EHRH.
European Medicines Agency Evaluation of Medicines for Human Use London, 8 May 2007 Doc. Ref. EMEA/HMPC/260019/2006 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON BETULA
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON EQUISETUM ARVENSE L., HERBA
European Medicines Agency Evaluation of Medicines for Human Use London, 31 October 2007 Doc. Ref. EMEA/HMPC/394894/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON HEDERA HELIX L., FOLIUM
European Medicines Agency Evaluation of Medicines for Human Use London, 14 January 2010 Doc. Ref. EMA/HMPC/289430/2009 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON
More informationGuide to Registration of Homeopathic Veterinary Medicinal Products
Guide to Registration of Homeopathic Veterinary Medicinal Products AUT-G0047-3 16 NOVEMBER 2012 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use. Superseded COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL
European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL London, 3 July 2008 Doc. Ref. EMEA/HMPC/394894/2007 COMMUNITY HERBAL MONOGRAPH ON EQUISETUM
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Venaforce Varicose Veins gastro-resistant tablets Horse Chestnut seed dry extract
: INFORMATION FOR THE USER Venaforce Varicose Veins gastro-resistant tablets Horse Chestnut seed dry extract Read all of this leaflet carefully before you start taking this product because it contains
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL
European Medicines Agency Evaluation of Medicines for Human Use London, 14 January 2009 Doc. Ref.: EMEA/HMPC/591648/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationPublic Assessment Report. Mebeverine hydrochloride 50mg/5ml Oral Suspension. (Mebeverine hydrochloride) UK Licence No: PL 44710/0024
Public Assessment Report Mebeverine hydrochloride 50mg/5ml Oral Suspension (Mebeverine hydrochloride) UK Licence No: PL 44710/0024 Kinedexe UK Limited 1 LAY SUMMARY Mebeverine hydrochloride 50mg/5ml Oral
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ECHINACEA PALLIDA (NUTT.) NUTT., RADIX
European Medicines Agency Evaluation of Medicines for Human Use London, 16 July 2009 Doc. Ref.: EMEA/HMPC/332350/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ECHINACEA
More informationPublic Assessment Report Scientific discussion. Prospan, oral solution (Hedera helix L. folium; dry extract (DER 5-7.
Public Assessment Report Scientific discussion Prospan, oral solution (Hedera helix L. folium; dry extract (DER 5-7.5:1); ethanol 30%) Asp. no: 2008-0572 This module reflects the scientific discussion
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Echinaforce Cold & Flu oral drops Echinacea purpurea herb & root tinctures
PACKAGE LEAFLET: INFORMATION FOR THE USER Echinaforce Cold & Flu oral drops Echinacea purpurea herb & root tinctures Read all of this leaflet carefully before you start taking this product because it contains
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON THYMUS VULGARIS L. AND THYMUS ZYGIS L., HERBA
European Medicines Agency Evaluation of Medicines for Human Use London, 8 May 2007 Doc. Ref. EMEA/HMPC/234113/2006 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON THYMUS
More informationDecentralised Procedure. Public Assessment Report. Budesonid Sandoz 32 / 64 Mikrogramm/Sprühstoß Nasenspray, Suspension.
Decentralised Procedure Public Assessment Report Budesonid Sandoz 32 / 64 Mikrogramm/Sprühstoß Nasenspray, Suspension Budesonide DE/H/0933/001-002/DC Applicant: Sandoz Pharmaceuticals GmbH Reference Member
More information100 ml of the syrup contain 825 mg of ivy leaf dry extract (Hedera helix L., folium) ( 4-8:1). Extraction solvent: ethanol 30% (m/m).
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Hedussin syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 100 ml of the syrup contain 825 mg of ivy leaf dry extract (Hedera helix L.,
More informationAtrosan Devil s Claw film-coated tablets
: INFORMATION FOR THE USER Atrosan Devil s Claw film-coated tablets Read all of this leaflet carefully before you start taking this product because it contains important information for you. Always take
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Harpatinum, capsule, soft Harpagophytum procumbens D.C. / H. zeyheri Decne (Devil s claw), radix, dry extract (4.4-5.0:1), ethanol 60 % (V/V) SE/H/1640/01/DC
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ALTHAEA OFFICINALIS L., RADIX
European Medicines Agency Evaluation of Medicines for Human Use London, 14 May 2009 Doc. Ref.: EMEA/HMPC/98717/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ALTHAEA
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Helaflex, film-coated tablet (Harpagophytum procumbens (Burch) DC (devil s claw) dried root, dry extract (4.4-5.0:1) ethanol 60 %) SE/H/1561/01/MR This module
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL
European Medicines Agency Evaluation of Medicines for Human Use London, 6 August 2007 Doc. Ref. EMEA/HMPC/263293/2006 Corr. COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON SOLIDAGO VIRGAUREA L., HERBA
European Medicines Agency Evaluation of Medicines for Human Use London, 4 September 2008 Doc. Ref. EMEA/HMPC/285758/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationPackage Leaflet: Information for the user. Digestisan oral drops
Package Leaflet: Information for the user Digestisan oral drops Read all of this leaflet carefully before you start taking this product because it contains important information for you. Always take this
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON VITEX AGNUS-CASTUS L., FRUCTUS
European Medicines Agency Evaluation of Medicines for Human Use London, 17 September 2009 Doc. Ref.: EMEA/HMPC/144006/2009 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON VALERIANA OFFICINALIS L., RADIX AND HUMULUS LUPULUS L.
European Medicines Agency Evaluation of Medicines for Human Use London, 14 May 2009 Doc. Ref.: EMEA/HMPC/585558/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON VALERIANA
More informationDecentralised Procedure. Public Assessment Report. Lorazepam-neuraxpharm 1/ 2,5 mg Schmelztabletten. Lorazepam DE/H/4558/ /DC
Decentralised Procedure Public Assessment Report Lorazepam-neuraxpharm 1/ 2,5 mg Schmelztabletten Lorazepam DE/H/4558/001-002/DC Applicant: neuraxpharm Arzneimittel GmbH, Germany Reference Member State
More informationEuropean Medicines Agency. Superseded COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON SALVIA OFFICINALIS L.
European Medicines Agency COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL London, 12 November 2009 Doc. Ref.: EMA/HMPC/331653/2008 COMMUNITY HERBAL MONOGRAPH ON SALVIA OFFICINALIS L., FOLIUM DISCUSSION
More information1. What Faslodex is and what it is used for
Package leaflet: Information for the user Faslodex 250 mg solution for injection Fulvestrant Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationGeneral Concepts in the European Pharmacopoeia. Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe
General Concepts in the European Pharmacopoeia Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe General notices Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All
More informationPackage leaflet: Information for the patient. ERWINASE 10,000 Units, Powder for solution for injection
PACKAGE LEAFLET 1 Package leaflet: Information for the patient ERWINASE 10,000 Units, Powder for solution for injection (Asparaginase from Erwinia chrysanthemi; Erwinia L-asparaginase) Read all of this
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON MELILOTUS OFFICINALIS (L.) LAM., HERBA
European Medicines Agency Evaluation of Medicines for Human Use London, 31 October 2007 Doc. Ref. EMEA/HMPC/354177/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON
More informationEprosartan 300 mg, 400 mg and 600 mg Film-coated Tablets. (Eprosartan mesilate) PL 37222/
Eprosartan 300 mg, 400 mg and 600 mg Film-coated Tablets (Eprosartan mesilate) PL 37222/0027-29 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps taken for assessment Steps
More informationPublic Assessment Report Scientific discussion. Ivabradine Grindeks 5 mg and 7.5 mg and filmcoated. Ivabradine hydrochloride ES/H/0375/ /DC
Public Assessment Report Scientific discussion Ivabradine Grindeks 5 mg and 7.5 mg and filmcoated tablets Ivabradine hydrochloride ES/H/0375/001-002/DC Registration number in Spain: 81.898, 81.899 This
More informationDecentralised Procedure. Public Assessment Report. Memantin AbZ 10 mg/20 mg Filmtabletten ; Starterpack
Decentralised Procedure Public Assessment Report Memantin AbZ 10 mg/20 mg Filmtabletten ; Starterpack Memantin-ratiopharm Starterpackung 5 mg /10 mg /15 mg /20 mg Filmtabletten ;10 mg/20 mg Filmtabletten
More informationPublic Assessment Report. Scientific discussion. Granon (Acetylcysteine) DK/H/2352/ /MR. Date:
Public Assessment Report Scientific discussion Granon (Acetylcysteine) DK/H/2352/001-002/MR Date: 25-06-2015 This module reflects the scientific discussion for the approval of Granon. The procedure was
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., HERBA
European Medicines Agency Evaluation of Medicines for Human Use London, 4 September 2008 Doc. Ref. EMEA/HMPC/202966/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationSCIENTIFIC DISCUSSION. Antimycobacterial (J04AC01).
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): International Nonproprietary Name: Pharmaco-therapeutic
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate
More informationEchinaforce Hot Drink
Package Leaflet: Information for the user Echinaforce Hot Drink Cold & Flu Echinacea concentrate for oral solution Echinacea purpurea herb & root tinctures Read all of this leaflet carefully before you
More informationQUALITY OF HERBAL MEDICINAL PRODUCTS: PRESENT REQUIREMENTS
QUALITY OF HERBAL MEDICINAL PRODUCTS: PRESENT REQUIREMENTS Phytopharm 2015 Bonn, 21 24 July 2015 1 Dr. Barbara Steinhoff Bundesverband der Arzneimittel-Hersteller CONTENTS Production of herbal starting
More informationPublic Assessment Report. Scientific discussion MINOXIDIL AT/H/0638/ /DC. Date:
CMDh/223/2005 February 2014 Public Assessment Report Scientific discussion Alocutan 20 mg/ml Spray zur Anwendung auf der Haut, Lösung, Alocutan 50 mg/ml Spray zur Anwendung auf der Haut, Lösung MINOXIDIL
More informationUnited Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE
United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Forthyron
More informationPackage leaflet: Information for the patient. Heparin Sodium BP 1000 IU/L in 0.9% w/v Sodium Chloride IV Infusion. Active substance: Heparin Sodium
Package leaflet: Information for the patient Heparin Sodium BP 1000 IU/L in 0.9% w/v Sodium Chloride IV Infusion Active substance: Heparin Sodium Read all of this leaflet carefully before you are given
More informationSummary Public Assessment Report. Generics. Triflu Paracetamol, Ascorbic acid, Pheniramine maleate MT/H/0172/001/DC
CMDh/305/2013 July 2014, Rev.01 Summary Public Assessment Report Generics Triflu Paracetamol, Ascorbic acid, Pheniramine maleate MT/H/0172/001/DC Date: 17 th August, 2016 Summary PAR Generics 1/3 Summary
More informationPotential Grounds for Revocation of a Traditional Herbal Registration
Potential Grounds for Revocation of a Traditional Herbal Registration By Dr Rosanna Cooper In this article we will be exploring the potential grounds for revocation of the Traditional Herbal Registration
More informationGuideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1
5 April 2016 EMA/HMPC/71049/2007 Rev. 2 Committee on Herbal Medicinal Products (HMPC) Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal
More informationGuidance for Pharmacists on the Safe Supply of Non-Prescription Levonorgestrel 1500mcg for Emergency Hormonal Contraception
Guidance for Pharmacists on the Safe Supply of Non-Prescription Levonorgestrel 1500mcg for Emergency Hormonal Contraception Pharmaceutical Society of Ireland Version 4 December 2016 Updates made following
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET VERGO 16 1. Product Name Vergo 16, 16 mg, tablet. 2. Qualitative and Quantitative Composition Each tablet contains 16 mg of betahistine dihydrochloride. For the full list of excipients,
More informationPublic Assessment Report. Scientific discussion. Kaliumklorid "EQL Pharma" (Potassium chloride) DK/H/2662/001/DC. Date:
CMDh/223/2005 February 2014 Public Assessment Report Scientific discussion Kaliumklorid "EQL Pharma" (Potassium chloride) DK/H/2662/001/DC Date: 16-06-2017 This module reflects the scientific discussion
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Galexir, oral solution (Cynara scolymus (artichoke) dried leaf / Gentiana lutea (gentian) dried root /Curcuma longa (turmeric) dried rhizome, liquid extract,
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Echinagard, oral drops, solution (Echinacea purpurea (L.) Moench, fresh herb, expressed juice (1.7-2.5:1)) Asp no: 2008-0658 This module reflects the scientific
More informationExcipient Risk Assessment
Excipient Risk Assessment Richard O Sullivan- GMP Inspector GMP Conference 7 February 2017 Dublin Content Background 1 Guidance 2 HPRA Expectations 3 07/02/2017 2 Excipient Risk Assessment-Why? 07/02/2017
More informationDecentralised Procedure. Public Assessment Report. Zolmitriptan Renantos 2.5 mg Orodispersible film 5 mg Orodispersible film DE/H/2295/ /DC
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Zolmitriptan Renantos 2.5 mg Orodispersible film 5 mg Orodispersible film DE/H/2295/001-002/DC Applicant:
More informationParticular challenges of evaluation of herbal combination products
Particular challenges of evaluation of herbal combination products Reinhard Länger, PhD, Assoc. Prof. Austrian Medicines and Medical Devices Agency (AGES MEA/BASG) Dept. for Herbal, Homeopathic & Veterinary
More informationPATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:
SCHEDULING STATUS: S2 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: TEXA 10 mg (tablets) TEXA SYRUP (syrup) Read this entire leaflet carefully before you start taking TEXA. Keep this leaflet. You
More informationDecentralised Procedure. Public Assessment Report
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Clozapin Regiomedica 50 mg/ml Suspension zum Einnehmen Clozamedica 50 mg/ml Suspension zum Einnehmen
More informationHERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK. Presented by: Mariam Aslam
HERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK Presented by: Mariam Aslam ESCOP European Scientific Cooperative On Phytotheapy (ESCOP) Founded in June 1989 as an umbrella
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON RUSCUS ACULEATUS L., RHIZOMA
European Medicines Agency Evaluation of Medicines for Human Use London, 7 September 2007 Doc. Ref. EMEA/HMPC/261938/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON
More informationDiscussion at the HMPC January March Draft agreed by Quality Working Party April Adoption by CHMP for release for consultation 26 May 2005
1 2 3 4 5 05 June 2018 EMA/HMPC/162241/2005 1 Rev. 3 6 7 8 9 Guideline on specifications: test procedures and acceptance criteria for herbal substances 2, herbal preparations 3 and herbal 4 /traditional
More informationRequirements to the Registration of Medicinal products in the Republic of Armenia
Requirements to the Registration of Medicinal products in the Republic of Armenia Yerevan 2010 Requirements to the Registration of Medicinal products in the Republic of Armenia Current requirements to
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ZADITEN 1 mg/5 ml Oral Solution. Ketotifen (as Ketotifen hydrogen fumarate)
PACKAGE LEAFLET: INFORMATION FOR THE USER ZADITEN 1 mg/5 ml Oral Solution Ketotifen (as Ketotifen hydrogen fumarate) Read all of this leaflet carefully because it contains important information for you.
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION 1 INTRODUCTION This application has been submitted to the EMEA for the CHMP to issue a scientific opinion in accordance with Article 58 of Regulation (EC) No 726/2004, in the context
More informationREGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011.
REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011. CHAPTER I Scope and definitions. Article 1 Scope.
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. GRAZAX 75,000 SQ-T oral lyophilisate
PACKAGE LEAFLET: INFORMATION FOR THE USER GRAZAX 75,000 SQ-T oral lyophilisate Standardised allergen extract of grass pollen from Timothy (Phleum pratense) Read all of this leaflet carefully before you
More informationPublic Assessment Report. Scientific discussion. Pentasa Compact 4 g, prolonged-release granules. (mesalazine) NL License RVG:
Public Assessment Report Scientific discussion Pentasa Compact 4 g, prolonged-release granules (mesalazine) NL License RVG: 114015 Date: 30 March 2015 This module reflects the scientific discussion for
More informationHedelix Cough Effervescent Tablets are used to relieve symptoms of chronic inflammatory bronchial conditions; for colds affecting the airways.
Package leaflet: Information for the patient Hedelix Cough Effervescent Tablets 50 mg Active substance: ivy leaf dry extract Read all of this leaflet carefully before you start taking this medicine because
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use. Superseded COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL
European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON LINUM USITATISSIMUM L., SEMEN DISCUSSION IN THE DRAFTING
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON LINUM USITATISSIMUM L., SEMEN
European Medicines Agency Evaluation of Medicines for Human Use London, 26 October 2006 Doc. Ref: EMEA/HMPC/340849/2005 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationRead all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Package leaflet: Information for the patient Hedelix Effervescent Tablets Active substance: ivy leaf dry extract Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPublic Assessment Report. Scientific discussion. Acetylcysteine YES 600 mg, effervescent tablets. (acetylcysteine) NL/H/2975/001/DC
Public Assessment Report Scientific discussion Acetylcysteine YES 600 mg, effervescent tablets (acetylcysteine) NL/H/2975/001/DC Date: 4 March 2015 This module reflects the scientific discussion for the
More informationPackage leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid
Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid Read all of this leaflet carefully before you are given this medicine because it contains important
More informationPublic Assessment Report. Scientific discussion. Mogilarta. (Telmisartan and hydrochlorothiazide) DK/H/2306/ /DC.
Public Assessment Report Scientific discussion Mogilarta 40 mg/12.5 mg, 80 mg/12.5 mg and 80 mg/25 mg tablets (Telmisartan and hydrochlorothiazide) DK/H/2306/001-003/DC 17 November 2014 This module reflects
More informationDIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004
30.4.2004 Official Journal of the European Union L 136/85 DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 amending, as regards traditional herbal medicinal products,
More informationNon-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients
Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Pharmaceutical Society of Ireland Version 3 October 2017 Updates made following the enactment
More informationPackage leaflet: Information for the patient. Selincro 18 mg film-coated tablets nalmefene
Package leaflet: Information for the patient Selincro 18 mg film-coated tablets nalmefene Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the patient. Histaclar 10 mg Film-coated Tablets loratadine
Package leaflet: Information for the patient Histaclar 10 mg Film-coated Tablets loratadine Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPublic Assessment Report. Scientific discussion. Acetylsalicylzuur Disphar 500 mg and 1000 mg, oral powder. (acetylsalicylic acid)
Public Assessment Report Scientific discussion Acetylsalicylzuur Disphar 500 mg and 1000 mg, oral powder (acetylsalicylic acid) NL/H/3464/001-002/DC Date: 21 June 2017 This module reflects the scientific
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL
European Medicines Agency Evaluation of Medicines for Human Use London, 11 July 2008 Doc. Ref. EMEA/HMPC/513617/2006 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HUMULUS
More informationPackage leaflet: Information for the user. Raxone 150 mg film-coated tablets idebenone
Package leaflet: Information for the user Raxone 150 mg film-coated tablets idebenone This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 16 March 2006 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationGuideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1
1 2 3 8 August 2012 EMA/HMPC/71049/2007 Rev. 1 Committee on Herbal Medicinal Products (HMPC) 4 5 6 7 Guideline on the use of the CTD format in the preparation of a registration application for traditional
More information